Switch theme
Sign up to access all valuation multiples
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
2019
76
Last FY Revenue n/a
LTM EBITDA -$73.4M
-$64.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alto Neuroscience has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$73.4M.
In the most recent fiscal year, Alto Neuroscience achieved revenue of n/a and an EBITDA of -$59.6M.
Alto Neuroscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alto Neuroscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$73.4M | XXX | -$59.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$70.7M | XXX | -$68.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$64.7M | XXX | -$61.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alto Neuroscience's stock price is $3.
Alto Neuroscience has current market cap of $69.8M, and EV of -$64.5M.
See Alto Neuroscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$64.5M | $69.8M | XXX | XXX | XXX | XXX | $-2.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alto Neuroscience has market cap of $69.8M and EV of -$64.5M.
Alto Neuroscience's trades at n/a EV/Revenue multiple, and 1.1x EV/EBITDA.
Equity research analysts estimate Alto Neuroscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alto Neuroscience has a P/E ratio of -1.1x.
See valuation multiples for Alto Neuroscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $69.8M | XXX | $69.8M | XXX | XXX | XXX |
| EV (current) | -$64.5M | XXX | -$64.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlto Neuroscience's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
Alto Neuroscience's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alto Neuroscience's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alto Neuroscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 53% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alto Neuroscience acquired XXX companies to date.
Last acquisition by Alto Neuroscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Alto Neuroscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alto Neuroscience founded? | Alto Neuroscience was founded in 2019. |
| Where is Alto Neuroscience headquartered? | Alto Neuroscience is headquartered in United States of America. |
| How many employees does Alto Neuroscience have? | As of today, Alto Neuroscience has 76 employees. |
| Who is the CEO of Alto Neuroscience? | Alto Neuroscience's CEO is Dr. Amit Etkin, M.D.,PhD. |
| Is Alto Neuroscience publicy listed? | Yes, Alto Neuroscience is a public company listed on NYS. |
| What is the stock symbol of Alto Neuroscience? | Alto Neuroscience trades under ANRO ticker. |
| When did Alto Neuroscience go public? | Alto Neuroscience went public in 2024. |
| Who are competitors of Alto Neuroscience? | Similar companies to Alto Neuroscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alto Neuroscience? | Alto Neuroscience's current market cap is $69.8M |
| Is Alto Neuroscience profitable? | Yes, Alto Neuroscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alto Neuroscience? | Alto Neuroscience's last 12 months EBITDA is -$73.4M. |
| What is the current EV/EBITDA multiple of Alto Neuroscience? | Current EBITDA multiple of Alto Neuroscience is 0.9x. |
| What is the current FCF of Alto Neuroscience? | Alto Neuroscience's last 12 months FCF is -$50.3M. |
| What is the current EV/FCF multiple of Alto Neuroscience? | Current FCF multiple of Alto Neuroscience is 1.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
